Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 110 publications
Leveraging Homologous Recombination Deficiency via the Repositioned Prodrug CB1954.
Journal: bioRxiv : the preprint server for biology
Published: July 17, 2026
The PRIME trial: An investigator-initiated, multicentre, phase II study of the poly(ADP-ribose) polymerase inhibitor olaparib in isocitrate dehydrogenase (IDH)-mutated relapsed/refractory acute myeloid leukaemia and myelodysplastic syndromes.
Journal: British journal of haematology
Published: July 02, 2026
Tumor Growth Rate (TGR) Analysis Predicts Survival in a Multicenter Phase II Study of the PARP Inhibitor Pamiparib (BGB-290) with Temozolomide in Recurrent IDH-Mutant Gliomas (ABTC-1801).
Journal: AJNR. American journal of neuroradiology
Published: February 19, 2026
CellPyAbility: automated image analysis for high-throughput dose-response screening.
Journal: Bioinformatics (Oxford, England)
Published: February 16, 2026
Synthesis and Biological Evaluation of Colibactin Derivatives.
Journal: ACS chemical biology
Published: December 19, 2025
Novel Strategies for Improved Treatment of O6-Methylguanine-DNA Methyltransferase Promoter-Methylated Glioma.
Journal: Medical research archives
Published: October 31, 2025
DNA damage response profile distinguishes poor-acting gliomas with shared methylome signatures.
Journal: Neuro-oncology
Published: September 01, 2025
Glioblastoma in adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.
Journal: Neuro-oncology
Published: August 19, 2025
On-target toxicity limits the efficacy of CDK11 inhibition against cancers with 1p36 deletions.
Journal: bioRxiv : the preprint server for biology
Published: August 06, 2025
Systemic administration of an RNA binding and cell-penetrating antibody targets therapeutic RNA to multiple mouse models of cancer.
Journal: Science translational medicine
Published: July 16, 2025
Phase I/II and window-of-opportunity study of pamiparib and metronomic temozolomide for recurrent isocitrate dehydrogenase mutant gliomas.
Journal: Neuro-oncology
Published: July 14, 2025
Last Updated: 09/26/2026